TNDM 8-K
Tandem Diabetes Care Inc (TNDM)
8-K
2024-05-16
For: 2024-05-10
View Original
Added on
April 12, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 8-K
____________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 10, 2024
____________________________
(Exact name of registrant as specified in its charter)
____________________________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| (Zip Code) | ||||||||||||||
| (Address of principal executive offices) | ||||||||||||||
Registrant’s telephone number, including area code: (858 ) 366-6900
N/A
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
____________________________
Item 1.01 Entry into a Material Definitive Agreement.
On May 10, 2024, Tandem Diabetes Care, Inc., a Delaware corporation (the “Company”) and Unomedical a/s, a Danish corporation and a subsidiary of the ConvaTec Group (“Unomedical”), entered into Amendment Number 1 (“Amendment 1”) to the Distributor Agreement, dated as of January 14, 2022, between the Company and Unomedical, under which Unomedical manufactures, tests, sterilizes and packs all of the infusion sets under the Company’s brands (the “Original Agreement”). Under Amendment 1, the term of the Original Agreement is extended, and certain definitions and terms and conditions related to distributorship, additional products, manufacturing, labeling, product specifications, purchase commitments and other matters are amended.
The foregoing description of Amendment 1 does not purport to be complete and is qualified in its entirety by reference to the full text of Amendment 1, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ending June 30, 2024.
Item 8.01 Other Events.
On May 13, 2024, Health Canada approved the addition of Trurapi U-100 to the list of compatible insulins that can be used with the Company’s t:slim X2 pump with Control-IQ technology in Canada.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Number | Description | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Tandem Diabetes Care, Inc. | ||||||||
| By: | /s/ SHANNON M. HANSEN | |||||||
| Shannon M. Hansen | ||||||||
| Chief Legal, Privacy & Compliance Officer; Secretary | ||||||||
Date: May 16, 2024
3